Johnson David Michael
- SEC CIK
- 0001808098
No open-market purchases or sales filed in the past year.
Current role at each company
- ZNTL Zentalis Pharmaceuticals, Inc.Directoras of Jun 18, 2026
- AURA Aura Biosciences, Inc.Directoras of Jun 15, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Johnson David Michael as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
AURA Aura Biosciences, Inc.
Director10 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 14, 2022 (view filing) | Jun 10-13 | 4 days | Johnson David MichaelDirector | PPurchase | +20.0K | $14.31 | +$286.1K | New position10.0K after | 4 lots |
| Jun 14, 2022 (view filing) | Jun 10-13 | 4 days | Johnson David MichaelDirector | PPurchase | +30.0K | $14.34 | +$430.2K | New position30.0K after | 2 lots |
| Dec 15, 2022 (view filing) | Dec 1 | 14 daysLate | Johnson David MichaelDirector | PPurchase | +10.0K | $12.37 | +$123.7K | +200.0%15.0K after | 2 lots |
| Dec 30, 2022 (view filing) | Dec 28 | 2 days | Johnson David MichaelDirector | PPurchase | +4.00K | $9.75 | +$39.0K | +30.8%17.0K after | 2 lots |
| Jan 9, 2023 (view filing) | Jan 5-6 | 4 days | Johnson David MichaelDirector | PPurchase | +2.00K | $10.41 | +$20.8K | +12.5%18.0K after | 4 lots |
| Oct 5, 2023 (view filing) | Oct 3-4 | 2 days | Johnson David MichaelDirector | PPurchase | +20.1K | $8.38 | +$168.2K | +66.9%50.1K after | 2 lots |
| Nov 9, 2023 (view filing) | Nov 7-8 | 2 days | Johnson David MichaelDirector | PPurchase | +85.6K | $7.18 | +$615.0K | +171.0%135.7K after | 2 lots |
| Nov 9, 2023 (view filing) | Nov 7-8 | 2 days | Johnson David MichaelDirector | PPurchase | +114.0K | $7.19 | +$820.0K | New position75.0K after | 4 lots |
| May 20, 2025 (view filing) | May 16 | 4 days | Johnson David MichaelDirector | PPurchase | +20.0K | $4.90 | +$98.0K | +13.7%166.2K after | |
| May 20, 2025 (view filing) | May 16 | 4 days | Johnson David MichaelDirector | PPurchase | +5.00K | – | – | –5.00K after | Derivative |
ZNTL Zentalis Pharmaceuticals, Inc.
Director2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 4, 2021 (view filing) | Oct 4 | Same day | Johnson David MichaelDirector | SSale | −12.9K | $66.35 | −$855.6K | −13.7%81.0K after | 3 lots |
| Nov 13, 2023 (view filing) | Nov 10 | 3 days | Johnson David MichaelDirector | PPurchase | +17.0K | $9.88 | +$168.0K | +13.3%144.4K after |